title: CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.
abstract: We report that CD39-expressing-melanoma cells inhibited both T-cell proliferation and the generation of cytotoxic effectors in an adenosine-dependent manner, and that treatment with a CD39-blocking antibody alleviated tumor-mediated immunosuppression. Thus, blocking CD39 ectonucleotidase may represent a novel immunotherapeutic strategy to restore antitumor immunity.
authors.affiliation: IRCM, Institut de Recherche en Cancérologie de Montpellier , INSERM U1194, Université Montpellier , Montpellier, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bonnefoy
authors.affiliation: OREGA Biotech ; Ecully, France.
authors.forename: Jérémy
authors.initials: J
authors.lastname: Bastid
authors.affiliation: OREGA Biotech ; Ecully, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Alberici
authors.affiliation: Laboratoire Immunologie Dermatologie & Oncologie, Institut National de la Santé et de la Recherche Médicale (INSERM U976) , Université Paris Diderot , Paris, France.
authors.forename: Armand
authors.initials: A
authors.lastname: Bensussan
authors.affiliation: IRCM, Institut de Recherche en Cancérologie de Montpellier , INSERM U1194, Université Montpellier , Montpellier, France ; Département d'Immunologie; Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine, Université de Montpellier , Montpellier, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Eliaou
keywords: CD39, immune checkpoints, A2A receptor, adenosine, PD1